Alkermes plc (ALKS)
- Previous Close
24.01 - Open
23.86 - Bid 23.76 x 700
- Ask 23.79 x 700
- Day's Range
23.62 - 24.14 - 52 Week Range
22.01 - 33.71 - Volume
1,744,429 - Avg. Volume
1,969,019 - Market Cap (intraday)
4.02B - Beta (5Y Monthly) 0.55
- PE Ratio (TTM)
7.76 - EPS (TTM)
3.06 - Earnings Date May 1, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
35.55
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
www.alkermes.com2,100
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: ALKS
Performance Overview: ALKS
Trailing total returns as of 4/18/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ALKS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ALKS
Valuation Measures
Market Cap
4.02B
Enterprise Value
3.62B
Trailing P/E
7.76
Forward P/E
9.80
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.42
Price/Book (mrq)
3.34
Enterprise Value/Revenue
2.18
Enterprise Value/EBITDA
6.97
Financial Highlights
Profitability and Income Statement
Profit Margin
21.39%
Return on Assets (ttm)
12.81%
Return on Equity (ttm)
46.22%
Revenue (ttm)
1.66B
Net Income Avi to Common (ttm)
519.16M
Diluted EPS (ttm)
3.06
Balance Sheet and Cash Flow
Total Cash (mrq)
773.49M
Total Debt/Equity (mrq)
30.95%
Levered Free Cash Flow (ttm)
204.21M